The objective of this investigation was to differentiate the roles of P-glycoprotein (Pgp), multidrug resistance-associated protein 2 (Mrp2), and CYP3A on saquinavir ( 
Saquinavir [SQV, (N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide]
, is a first-in-class and potent HIV protease inhibitor for the treatment of HIV infection (Roche Laboratories, 2001 ). After oral administration, SQV pharmacokinetics in humans are characterized by low bioavailability with high individual variation (Figgitt and Plosker, 2000) . In healthy volunteers, the oral bioavailability of SQV when given alone was approximately 4% with a CV% Ͼ100% (Roche Laboratories, 2001 ). In humans, SQV undergoes extensive first-pass metabolism by CYP3A4, and its major route of excretion is through the bile (Roche Laboratories, 2001) .
SQV is a known substrate of several intestinal transporters and CYP3A. In MDCKII cell lines overexpressing ABCB1 and ABCC2, our group and others found that MDR1 and MRP2 were responsible for SQV secretory transport, respectively (Huisman et al., 2002; Williams et al., 2002) , whereas MRP1 appeared to be involved in SQV absorptive transport (Williams et al., 2002) . A recent study by our group showed that SQV is also a substrate of organic anion-transporting polypeptide OATP-A (SLC21A3) (Su et al., 2004) . In human liver and small intestinal microsomes, SQV was metabolized mainly to monohydroxylated compounds (Fitzsimmons and Collins, 1997; Eagling et al., 2002) . The metabolism of SQV occurs primarily by CYP3A4. In the presence of a specific CYP3A4 inhibitor, ketoconazole, SQV metabolism in small intestinal microsomes was completely inhibited (Fitzsimmons and Collins, 1997; Eagling et al., 2002) .
Pgp is known to be a major secretory transporter in the intestine, brain, and many other organs. The impact of Pgp on oral bioavail-ability, intestinal excretion, and tissue distribution has been shown in mdr1a knockout mice (Schinkel et al., 1997a; Sparreboom et al., 1997) . In humans, Pgp inhibition caused a significant decrease in digoxin intestinal excretion (Drescher et al., 2003) , whereas rifampinup-regulated intestinal Pgp expression appeared to be responsible for a decrease in digoxin oral bioavailability (Greiner et al., 1999) .
MRP2, expressed primarily in the canalicular membrane of hepatocytes and the apical membrane of enterocytes (Suzuki and Sugiyama, 2002) , is believed to be a major secretory transporter in the biliary excretion of glutathione, glucuronide, and sulfate conjugates and many nonconjugated organic anions (Keppler et al., 1997; Williams et al., 2002) . Mrp2 deficiency, as seen in TR Ϫ rats or Eisai hyperbilirubinemic rats, results not only in decreased biliary secretion of organic anions and conjugates but also in significantly reduced bile flow (Paulusma et al., 1996; Suzuki and Sugiyama, 2002) . MRP2/ Mrp2 appears to play a minor role in intestinal absorption and secretion, especially when Pgp is involved even though they have similar intestinal localization. Furthermore, the oral absorption of grepafloxacin, a Mrp2 and Pgp substrate, was not significantly enhanced by the inhibition of Mrp2; however, biliary excretion was significantly reduced, suggesting differential roles for Pgp and Mrp2 in the intestine and liver (Naruhashi et al., 2002) .
Although it is known that Pgp, MRP2, and CYP3A4 contribute to the oral bioavailability and disposition of many drugs, their differential roles in SQV oral absorption and disposition are not yet fully understood. In AIDS therapy, SQV is often given with a boosting agent, such as ritonavir (RTV), to improve SQV oral bioavailability and to reduce its individual variation (Buss et al., 2001; Plosker and Scott, 2003) . Such boosted SQV regimens result in increased C max and AUC, reduced intersubject variability, and decreased elimination t 1/2 (Buss et al., 2001; Plosker and Scott, 2003) . The mechanism of boosting therapy is widely thought to be the result of the inhibition of CYP3A (Kempf et al., 1997; Plosker and Scott, 2003) . However, the shortened elimination t 1/2 of SQV in boosting regimens cannot be fully explained by this hypothesis. Because RTV is a substrate and inhibitor of CYP3A4, Pgp, and MRP2 (Gutmann et al., 1999; Huisman et al., 2001 Huisman et al., , 2002 Williams et al., 2002) , the RTV boosting effect is likely to be a combined result of drug-drug interactions mediated by Pgp, MRP2, and CYP3A4. Recent evidence suggests that Pgp-mediated secretory transport may also play an important role in SQV oral bioavailability (Huisman et al., 2001; Sinko et al., 2004) . It is unclear whether the boosting effect resulting from Pgp inhibition is due to enhanced SQV oral absorption or diminished clearance or disposition. Furthermore, SQV is excreted mainly into the bile in humans (Roche Laboratories, 2001 ). Because SQV is a MRP2 substrate, MRP2 inhibition may also affect its pharmacokinetic behavior.
The present study was designed specifically to differentiate the roles of Pgp, Mrp2, and CYP3A on SQV oral absorption. In situ single-pass jejunal perfusion and portal vein-cannulated rats were used as study systems to exclude or minimize the confounding influence of first-pass hepatic metabolism. (Planting et al., 2005) , and product information is provided by Cayman Chemical (Ann Arbor, MI; www.caymanchem.com), respectively. Midazolam (MDZ) (Versed, 5 mg/ml; Roche Laboratories) was purchased through the Rutgers University Health Center Pharmacy. Other reagents and solvents used are the highest grade commercially available. C18 solid-phase extraction cartridges (SPEC ⅐ Plus ⅐ 3 ml ⅐ C18) were purchased from Ansys Diagnostics, Inc. (Lake Forest, CA).
Materials and Methods

Materials
Animals. Male Sprague-Dawley rats with or without portal vein cannulas, weighing 200 to 400 g and 2 to 3 months of age, were purchased from Hilltop Lab Animals (Scottsdale, PA). The rats were used in accordance with the protocols (01-014 and 03-033) approved by the Rutgers University Institutional Review Board-Use and Care of Animal Committee and housed in Association for Assessment and Accreditation of Laboratory Animal Care accredited facilities at Rutgers University. All animals were allowed to acclimate for a minimum of 2 to 3 days before the studies were initiated. Food and water were provided ad libitum. Before experiments, all animals were fasted overnight with free access to water.
In Situ Perfusion Studies. The single-pass perfusion was performed following a method published in the literature (Johnson et al., 2003) with modification. Briefly, rats were anesthetized by an i.m. injection of the ketamine (80 mg/kg) and xylazine (10 mg/kg) cocktail. Through a midline incision, the small intestine was exposed and an ϳ10-cm jejunum segment was externalized. The segment was cannulated with Teflon tubing at both proximal and distal ends. The inlet jejunal cannula was connected to an infusion pump (Harvard Apparatus Inc., Holliston, MA). The perfusate containing 100 M saquinavir with or without the inhibitor(s) in MES Ringer's buffer (pH 6.5) and with a trace amount of [ 14 C]saquinavir was perfused through the intestinal segment at a flow rate of 0.2 ml/min. The system was equilibrated for approximately 20 min before blood collection. The collective mesenteric vein for the segment was cannulated with polyethylene tubing for blood drainage. Before the mesenteric vein cannulation, a tail vein was cannulated using a 24-gauge i.v. catheter, and the animal was heparinized (ϳ90 U/kg). Freshly collected blood from naive rats and normal saline (8:2, v/v) were infused via a tail vein catheter at 0.3 ml/min. The blood drained from the mesenteric vein catheter was collected at 5-min intervals for approximately 30 min. During the experiment, a heating mat and a lamp were used to maintain the animal's body temperature. The exposed jejunal segment was covered with a saline-soaked gauze and plastic film. Blood samples were centrifuged at ϳ1000 g for 10 min to harvest plasma. All plasma samples were stored at Ϫ80°C until analysis.
Six dosing regimens were studied: SQV alone, SQV ϩ GF120918 (SQV ϩ GF), SQV ϩ MK571 (SQV ϩ MK), SQV ϩ MDZ, SQV ϩ GF ϩ MK, or SQV ϩ GF ϩ MDZ. Each group consisted of three or more rats. The concentrations of the inhibitors in the perfusate were 20 M (GF) and 100 M (MK and MDZ). Selection of a 100 M concentration for SQV, the solubility in the buffer system at pH 6.5, in the perfusate was to mimic the possible drug concentration at the absorption site during oral absorption in vivo. It was reported that GF120918 at 10 M produced complete inhibition of Pgp function in MDR1-MDCKII cells (Polli et al., 2001) , K i values of MK571 in various MRP2-overexpressed cell lines were Ͻ15 M (Shen et al., 1996; Leier et al., 2000) , and MDZ at 50 M inhibited more than 80% metabolite formation of SQV in human intestinal microsomes (Fitzsimmons and Collins, 1997) . To assure maximal inhibition, GF120918 at 20 M, MK571 at 100 M, and midazolam at 100 M were used in the perfusion studies.
Oral Dosing and Sampling. The SQV dosing solution (6 mg/ml) was prepared using a cosolvent mixture of ethanol-propylene glycol-distilled and deionized water (2:3:5, v/v/v). The GF120918 dosing solution (1 mg/ml) used the same solvent system. The MK571 dosing solution (3 mg/ml) was prepared with 1% Tween 80 in a mixture of dimethylsulfoxide, ethanol, propylene glycol, and saline (10:18:27:45, v/v/v/v). All solutions were prepared freshly before dosing.
The cosolvent of ethanol-propylene glycol-water has been commonly used as a dosing vehicle for SQV and GF1201918 in humans and animals (Kempf et al., 1997; Sinko et al., 2004) . Addition of 1% Tween 80 and 10% dimethylsulfoxide was necessary for dissolving MK571 and preventing MK571 from precipitating when mixed with SQV and GF120918. All cosolvents in the dosing vehicles represent the minimal amounts necessary to achieve solubilization, and the percentage of each component was within the recommended range for rats (Swindle and Adams, 1988) .
Portal vein-cannulated rats were given SQV at 20 mg/kg via oral gavage. GF120918 (3 mg/kg), MK571 (14 mg/kg), or MDZ (10 mg/kg) was coadministered with SQV. The animals were divided into six groups (n ϭ 3-7 rats/group) and given SQV alone (control), SQV ϩ GF, SQV ϩ MK, SQV ϩ 864 USANSKY ET AL.
at ASPET Journals on April 20, 2017 dmd.aspetjournals.org MDZ, SQV ϩ GF ϩ MK, or SQV ϩ GF ϩ MDZ. The dosing volume was ϳ2 ml. Blood samples (0.5 ml) were collected before (predose) and after dosing (10, 20, 40, 60, 90, 150, 240 , and 360 min). After each sample was taken, the catheter was flushed with 0.5 ml of saline containing 50 U of heparin to compensate for blood loss and to prevent the catheter from clogging. At the end of the study, animals were euthanized using an i.v. dose of pentobarbital at ϳ100 mg/kg. Plasma was harvested after centrifugation at ϳ1000g for 10 min. All samples were stored at Ϫ80°C until analysis.
The selection of an SQV dose of 20 mg/kg was based on the quantitation limit for the plasma samples on LC-MS/MS and its clinical relevance (SQV clinical dose: 600-1200 mg/dose or 8.6 -17 mg/kg for a 70-kg man) (Plosker and Scott, 2003) . On the basis of the mass ratios between SQV (100 M) and the inhibitors (20 M GF120918, 100 M MK571, and 100 M MDZ), doses of 3 mg/kg for GF120918, 14 mg/kg for MK571, and 10 mg/kg for MDZ were selected for SQV at 20 mg/kg.
Sample Analysis. Plasma samples were purified by solid-phase extraction using a literature method with modification (Frappier et al., 1998) . Briefly, 0.25 ml of plasma samples were mixed with 20 l of internal standard (2 g/ml quinidine) and 0.5 ml of 0.18 M ammonium acetate (pH 6.8) before extraction. After conditioning the C18 solid-phase extraction columns (SPEC ⅐ Plus ⅐ 3 ml ⅐ C18) with 1 ml of methanol and 1 ml of deionized and distilled water, plasma samples were loaded onto the columns, washed with 1 ml of water, and then eluted twice with 0.25 ml of methanol. The eluate (10 l) was injected directly onto a LC-MS/MS system.
The LC-MS/MS system consisted of a ThermoQuest Surveyor MS pump (ThermoQuest Co., San Jose, CA), a Surveyor autosampler, and a Finnigan LCQ DECA mass spectrometer (ThermoQuest Co.). SQV and quinidine (internal standard) eluted from a C18 column (Eclipse XDB-C18, Zorbax 2.1 ϫ 50 mm, 3.5 m, Agilent Technologies, Palo Alto, CA) using an isocratic mobile phase of 35% 2 mM ammonium acetate and 65% acetonitrile at a flow rate of 0.2 ml/min. The retention times of the analytes were 1.5 min (internal standard) and 2.2 min (SQV). By electron spray ionization and under positive ion mode, SQV was detected at m/z 671.43 m/z 570.4, its major metabolites (M2, M3, and M7, where M2 and M3 are stereo-isomers) (Fitzsimmons and Collins, 1997) were detected at m/z 687.4 3 m/z 568.4 (M7) and at m/z 687.4 3 m/z 586.4 (M2/M3 isomers eluted as a single peak), and quinidine was detected at m/z 325.2 3 m/z 307.1 and m/z 264.2. The quantitation limit of the assay was 1 ng/ml. The recovery of SQV in plasma samples after extraction was ϳ80%.
Data Analysis. Plasma concentrations of SQV were determined from calibration standard curves. Because of the unavailability of purified metabolites, the plasma concentrations of M2/3 and M7 were estimated using SQV calibration curves and denoted as SQV equivalent concentrations (e.g., nanogramequivalents per milliliter). Mesenteric blood concentration levels were relatively constant under the constant perfusion rate; hence, the average plasma concentrations of SQV and its metabolites in the mesenteric blood samples were used as a parameter for the extent of SQV intestinal absorption. Because M2, M3, and M7 account for ϳ90% of SQV metabolites formed in the intestinal tissues (Fitzsimmons and Collins, 1997) , the sum of unchanged SQV and these metabolites in the blood was considered as the total amount absorbed. On the basis of the cumulative total drug amount (SQV ϩ M237) in the blood (SQV blood/plasma concentration ratio ϳ1), the fraction absorbed (F a ) was determined as a fraction of perfused drug amount. The fraction of dose that survived from intestinal metabolism (F gut ) was estimated from the ratio of cumulative drug amounts between the parent and total SQV-related compounds.
Pharmacokinetic parameters for oral studies, such as maximum plasma concentration (C max ), the time to maximum concentration (T max ), area under the plasma concentration curve to the last measurable concentration (AUC 0 -t ) or to infinity (AUC 0 -ϱ ), elimination half-life (t 1/2 ), apparent volume of distribution (V d /F), and apparent clearance (CL/F) were analyzed using a noncompartmental analysis (WinNonlin Professional v4.1; Pharsight, Mountain View, CA). The fraction of dose that survived from intestinal metabolism (F gut ) was estimated from the AUC ratios between the parent and total SQV related compounds: F gut ϭ AUC SQV /(AUC SQV ϩ AUC M237 ), where M237 indicates M2/M3 and M7. The statistical differences between the parameters of dose groups were tested with one-way or two-way analysis of variance (GraphPad Prism v4; GraphPad Software, Inc., San Diego, CA), and statistical significance was defined as p Ͻ 0.05. All data are presented to three significant figures. The geometric means of C max and AUCs and their 90% confidence intervals were determined from log-transformed values and used for comparisons between groups.
Results
SQV Absorption and Metabolism in Rat Jejunum
. After a single-pass jejunal perfusion, SQV and its metabolites, M2/M3 and M7, were detected in the mesenteric plasma (Fig. 1) . The plasma concentrations were generally consistent within the 30-min drainage in each animal, demonstrating that the average plasma concentrations reflect the extent of SQV intestinal absorption. Minimal unexpected drug loss occurred during the experiments as the recovery of total radioactivity from the outlet perfusate and intestinal tissue was approximately 100% of perfused radioactivity.
When perfused alone, SQV absorption in the jejunal region was dmd.aspetjournals.org extremely low (average plasma concentration Ͻ25 ng-Eq/ml and F a Ͻ0.1%) ( Table 1 ). Moderate amounts of its hydroxylated metabolites, M2/M3 and M7, were also detected with F gut of 78%.
When perfused with GF120918, SQV absorption increased by ϳ24-fold, whereas MK only increased SQV F a by ϳ2-fold. The rank order of F a was SQV ϩ GF Ͼ SQV ϩ GF ϩ MDZ Ͼ SQV ϩ GF ϩ MK Ͼ SQV ϩ MDZ Ͼ SQV ϩ MK Ͼ SQV. All GF groups (SQV ϩ GF, SQV ϩ GF ϩ MK, and SQV ϩ GF ϩ MDZ) showed statistically higher plasma concentrations and F a than those in the control group ( p Ͻ 0.05) ( Table 1) . Based on the rank order, a synergistic effect between GF120918 and MK571 or MDZ was not observed. As expected, MDZ minimized SQV intestinal metabolism (F gut of ϳ96%).
Oral Pharmacokinetics of SQV. After oral administration to rats, SQV and its metabolites were detected in the portal circulation (Fig.  2) . SQV plasma concentrations were low and highly variable with C max of 0.0681 g/ml (CV% ϭ 110%) and AUC 0 -ϱ of 6.83 g ⅐ min/ml (CV% ϭ 102%) ( Table 2) . A large apparent volume of distribution (V d /F) of SQV (539 liters/kg) and a moderate apparent clearance (CL/F) (5.29 liters/min/kg) were observed. The elimination t 1/2 of SQV was ϳ2 h. The C max and AUC of M237 were also low and highly variable with F gut of 78% (Table 3 ). The T max values for the metabolites were similar to those for the parent compound.
Consistent with the in situ data, C max and AUCs of SQV in GF-treated groups were significantly higher than those for the non-GF treated groups (Table 2; Fig. 3 ). GF alone enhanced the C max and AUC of SQV by more than 20-fold, whereas MK571 and MDZ showed little effect (Ͻ3-fold increase in AUC) ( Table 2 ). The rank order of SQV AUC was SQV ϩ GF120918 Ͼ SQV ϩ GF ϩ MK Ͼ SQV ϩ GF ϩ MDZ Ͼ SQV ϩ MDZ Ͼ SQV ϩ MK Ͼ SQV. All GF-treated groups showed significantly higher C max and AUCs than those from the control group ( p Ͻ 0.05). In addition, the variations of C max and AUCs in all GF120918-treated groups were much less than those in the non-GF120918-treated groups (CV%: 30 -50% versus 80 -110%). However, the CV% of SQV C max and AUCs were not improved by the dual inhibition regimens (26 -31% for GF alone versus 26 -50% for the dual inhibition groups). Synergism between GF120918 and MK571 or between GF120918 and MDZ was not observed. These results once again demonstrate that Pgp controls SQV oral absorption and Pgp-mediated transport is responsible for its highly variable oral bioavailability.
In the presence of the inhibitors, M237 AUCs were approximately proportional to the AUCs of the parent with exceptions of SQV ϩ MK and SQV ϩ MDZ. Because MDZ is a CYP3A inhibitor, lowered metabolite AUC with coadministration of SQV and MDZ was expected. For the SQV ϩ MK group, decreased metabolite AUC may be caused by the limited data points in the terminal phase.
In Situ and in Vivo Correlation. To examine whether in vivo AUC measured from portal circulation can be used as a surrogate for the extent of oral absorption, a linear correlation test was performed (Fig. 4) . The observed F a values in situ and the AUC values measured from portal vein-cannulated rats were highly correlated (r 2 ϭ 0.876), suggesting a strong role of the intestine in the overall bioavailability of SQV.
Discussion
SQV, a potent first-in-class HIV protease inhibitor, has low and variable oral bioavailability (Roche Laboratories, 2001) . To understand the roles of secretory transporters and metabolizing enzymes in SQV boosting regimens, we investigated SQV intestinal and oral absorption in situ using a single-pass intestinal perfusion technique and in vivo in portal vein-cannulated rats under specific chemical inhibition of Pgp, Mrp2, and CYP3A. The individual roles of Pgp, Mrp2, and CYP3A were elucidated by specific chemical inhibition using GF120918 (a potent Pgp and breast cancer resistance protein inhibitor) (Hyafil et al., 1993) , MK571 (a specific inhibitor of Mrps) (König et al., 1999) , and MDZ (an inhibitor and substrate of CYP3A) (Cummins et al., 2003) . Because SQV is an inhibitor but not a substrate of breast cancer resistance protein (Gupta et al., 2004) and Mrp2 is the primary Mrp involved in SQV transport (Huisman et al., 2002) , the modulating effects of GF120918 and MK571 were considered to be approximations of Pgp and Mrp2 inhibition.
The in situ single-pass rat jejunal perfusion and in vivo portal vein-cannulated rats were selected as the study systems to exclude or minimize the confounding influence of first-pass hepatic metabolism and allow for the direct study of SQV oral absorption. The in situ single-pass intestinal perfusion system preserves the functions of intestinal transporters and enzymes better than in vitro systems, yet it isolates intestinal absorptive functions from possible systemic and hepatic interferences. The use of the perfusion system serves two purposes: to confirm putative modulation by Pgp, Mrp2, and CYP3A on SQV oral absorption and to validate whether the portal vein- a Statistically significantly higher from the control (SQV alone), P Ͻ 0.05.
FIG. 2. Plasma concentrations of SQV and its metabolites M2, M3, and M7 (M237)
in portal vein-cannulated rats after oral administration of SQV at 20 mg/kg. Data presented are means and SEs; n ϭ 7.
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at ASPET Journals on April 20, 2017 dmd.aspetjournals.org cannulated rats can be used as an in vivo system for oral absorption mechanism studies. The in vivo pharmacokinetic data were used mainly to draw conclusions related to SQV oral absorption rather than its elimination pharmacokinetics because inhibiting CYP3A would minimize the role of the liver altering SQV oral bioavailability (F) and the disposition parameters (such as CL/F and V d /F). Furthermore, the elimination t 1/2 measured in portal circulation may or may not be the same as that measured in systemic circulation, depending on the completeness of oral absorption. Our results show that SQV plasma concentrations in the mesenteric (in situ) and portal (in vivo) circulation resulting from the modulation of Pgp, Mrp2, and CYP3A were highly correlated, providing direct evidence that drug concentrations in the portal circulation reflect the extent of SQV oral absorption. By minimizing the role of the liver, we were able to show that the role of the intestine in determining the oral bioavailability and first-pass clearance of SQV is significant. As expected, in situ and in vivo SQV intestinal/oral absorption was low and highly variable, similar to literature observations in which rats were given 20 mg/kg and bioavailability was low (4%) and FIG. 3 . C max and AUC of saquinavir in portal vein-cannulated rats after oral administration of SQV at 20 mg/kg with or without Pgp, Mrp2, and CYP3A inhibitors. Data presented are means and SEs; n ϭ 3-7. ‫,ء‬ statistical difference from the control (SQV alone) (p Ͻ 0.05). The parameters were determined based on the concentrations of metabolites equivalent to SQV; n ϭ 3 to 7 rats/group. (Shibata et al., 2002) . Moderate amounts of metabolites (1 Ϫ F gut ϭ ϳ20%) seen in the mesenteric and portal circulation indicate that SQV intestinal metabolism is a not significant factor in its low oral bioavailability. However, decreased metabolite formation by MDZ reconfirmed that CYP3A is responsible for the intestinal firstpass loss of the drug. The significant effect of GF120918 on SQV F a , C max , and AUCs revealed that SQV oral absorption is controlled by the secretory efflux transporter Pgp and not by limited membrane permeability because of poor passive diffusion resulting from the equally poor physicochemical properties of SQV. The highly variable C max and AUCs in non-GF-treated groups compared with the reduced variability of the GF-treated groups supports the concept that Pgp-mediated transport is a key factor for causing individual variation in SQV oral bioavailability. In contrast, Mrp2 appears to be an insignificant player in SQV oral absorption. When compared with other groups, Mrp2 inhibition (SQV ϩ MK and SQV ϩ GF ϩ MK) appears to have caused a longer t 1/2 . Knowing that SQV is excreted mainly in the bile in rats (Paulusma et al., 1996) and Mrp2 is a major transporter to facilitate the biliary excretion of many drugs (Keppler et al., 1997; Williams et al., 2002) , the prolonged t 1/2 could be related to decreased biliary excretion under Mrp2 inhibition. However, because of the limitation of portal vein-cannulated rats for characterizing disposition parameters, further investigation of the role of Mrp2 in SQV elimination with i.v. administration and in bile duct-cannulated rats may lead to more definitive conclusions.
Dual inhibition of Pgp and Mrp2 or Pgp and CYP3A did not further improve the oral absorption of SQV nor further increase the exposure levels of the drug compared with Pgp inhibition alone. This result may be explained by the dominating effect of Pgp on SQV intestinal absorption and the limitation of the test systems for minimizing the functions of the transporters and enzymes in the liver and also demonstrates that intestinal Mrp2 and intestinal CYP3A play minor roles in SQV oral bioavailability.
Despite anatomical differences between humans and rats, the oral bioavailability of SQV in the two species is similar, both low (4%) and variable (Roche Laboratories, 2001; Shibata et al., 2002) . Perhaps this similarity is due to the structural and functional similarity between rodent Mdr1, Mrp2, and CYP3A and their human counterparts (i.e., MDR1, MRP2, and CYP3A4) (Schinkel, 1997b; König et al., 1999; Bogaards et al., 2000) , thus making the rat a relevant model for investigating SQV oral bioavailability in humans. Therefore, the roles of Pgp, Mrp2, and CYP3A in SQV oral absorption and intestinal metabolism revealed in the present study may be applicable to their roles in SQV boosting therapy in humans.
In conclusion, our study results provide, for the first time, direct and explicit evidence that Pgp controls SQV oral absorption and that Pgp-mediated transport is a key factor for causing the low, yet highly variable, oral bioavailability of the drug. It was also found that intestinal Mrp2 and intestinal CYP3A play minor roles in SQV oral bioavailability. The differential roles of Pgp, Mrp2, and CYP3A in SQV oral absorption strongly suggests that boosting occurs by means of transient alterations not only in metabolizing enzyme function but also in transporter function, thus broadening the current scientific perspective on optimizing clinical anti-HIV boosting strategies.
